Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 7/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 2/20 | 0.34 |
| ▸ | ACP1 | P24666 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL990761 | 0.78 | HDAC1 (0.39) | HDAC1HRH4HDAC3HDAC2TLR7 | |
| SCHEMBL989412 | 0.69 | MAPK14 (0.41) | HDAC1MAPK14 | |
| SCHEMBL991919 | 0.68 | MAPK14 (0.51) | ADORA1ADORA2AMAPK14 | |
| SCHEMBL990904 | 0.68 | MAPK14 (0.39) | HDAC1HDAC2ADORA1ADORA2AMAPK14 | |
| SCHEMBL218119 | 0.67 | ALOX15 (0.52) | — | |
| SCHEMBL29922600 | 0.66 | IDO1 (0.49) | HDAC1HRH4HDAC3HDAC2TLR7 | |
| SCHEMBL3650531 | 0.66 | IDO1 (0.49) | HDAC1HRH4HDAC3HDAC2TLR7 | |
| SCHEMBL990014 | 0.66 | TDP1 (0.39) | — | |
| SCHEMBL5258225 | 0.66 | DYRK1A (0.45) | ADORA2A | |
| SCHEMBL1341810 | 0.65 | TDP1 (0.43) | HRH4ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863310-B2 | Kinase inhibitors | ELI LILLY AND COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| US-20080227839-A1 | Kinase Inhibitors | ELI LILLY AND COMPANY | 2008-09-18 | — | — | US | disclosed |
| EP-1720862-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005080380-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227839-A1 | Kinase Inhibitors | ABL1, MAP3K20, MAP3K19 | HDAC1 886/4885HRH4 4118/4885HDAC3 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.